Birdwell, Christine E.
Fiskus, Warren https://orcid.org/0000-0002-7343-6214
Mill, Christopher P. https://orcid.org/0000-0003-0957-6009
Kadia, Tapan M. https://orcid.org/0000-0002-9892-9832
Daver, Naval https://orcid.org/0000-0001-7103-373X
DiNardo, Courtney D. https://orcid.org/0000-0001-9003-0390
Sasaki, Koji
Davis, John A.
Das, Kaberi https://orcid.org/0000-0003-4702-0386
Hou, Hanxi https://orcid.org/0000-0002-1951-3522
Jain, Antrix
Malovannaya, Anna https://orcid.org/0000-0003-2953-6485
Flores, Lauren B.
Pourebrahim, Rasoul https://orcid.org/0000-0003-1175-2032
Yuan, Selina
Su, Xiaoping
Ceribelli, Michele
Bhalla, Kapil N. https://orcid.org/0000-0001-5209-5126
Article History
Received: 27 July 2025
Revised: 25 November 2025
Accepted: 4 December 2025
First Online: 19 December 2025
Change Date: 9 March 2026
Change Type: Update
Change Details: The original online version of this article was revised: In the published version of our article, the (-log10 p value) on the y-axis for Figure 1D was calculated and displayed incorrectly. We have corrected the panel to show the properly calculated (-log10 p-value) on the y-axis. The original article has been corrected.
Change Date: 11 March 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-026-02911-8
Competing interests
: All authors declare they have no conflict of interests to disclose.
: RNA-Seq datasets have been deposited in GEO under Accession ID GSE297482. The mass spectrometry proteomics data for AML194 cells treated with mivebresib, dactolisib, and LCL161 have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with dataset identifier PXD063413. The compounds utilized and the primary data from the MIPE v5.0 screen have been deposited in PubChem under the following assay ID (AID): 2202231, 2202232, 2202233, 2202234, 2202235, 2202236 and 2202237.
: These studies were conducted in accordance with relevant guidelines and regulations and were approved by the Institutional Review Board of MD Anderson Cancer Center under protocols LAB01-473 and PA16-0468. All samples were collected and tested following approval under these protocols. Informed consent was obtained from all participants. All in vivo studies were approved by the IACUC at M.D. Anderson Cancer Center.